Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis - PubMed (original) (raw)
Review
. 2005 Nov;30(11):1949-62.
doi: 10.1038/sj.npp.1300850.
Affiliations
- PMID: 16123764
- DOI: 10.1038/sj.npp.1300850
Review
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis
R Grant Steen et al. Neuropsychopharmacology. 2005 Nov.
Abstract
A systematic review of the literature identified 64 published English-language papers that used proton (1H) magnetic resonance spectroscopy to measure N-acetylaspartate (NAA) concurrently in healthy controls and in patients with a diagnosis of schizophrenia (SZ). A total of 1209 controls and 1256 patients have been evaluated, with 88% of studies carried out at 1.5 T field strength, and 77% of studies focused on patients with chronic SZ. There is consistent evidence that NAA is reduced in a broad range of tissues in the SZ brain. Broad consensus (> or =10 studies) is emerging that NAA levels are reduced > or =5% in hippocampus and in both cortical gray matter (GM) and white matter (WM) of the frontal lobe. There is no evidence to support a hypothesis that relative NAA levels are reduced to a different degree in frontal lobe GM and WM, nor is there robust evidence of a difference in NAA levels between patients with first-episode and chronic SZ. Study reliability may be a problem, as most studies appear to be underpowered. With simple assumptions about the inherent difference in NAA levels between patients and controls, it can be calculated that a minimum sample size of approximately 39 patients and 39 controls is required for acceptable statistical power. Only three of 64 studies included enough subjects to have 80% power to detect a 10% NAA reduction in patients, and no studies were adequately powered to detect a 5% NAA reduction with 80% power.
Similar articles
- Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia.
Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A. Lim KO, et al. Arch Gen Psychiatry. 1998 Apr;55(4):346-52. doi: 10.1001/archpsyc.55.4.346. Arch Gen Psychiatry. 1998. PMID: 9554430 - Detection of metabolites in the white matter of frontal lobes and hippocampus with proton in first-episode treatment-naïve schizophrenia patients.
He ZL, Deng W, Li ML, Chen ZF, Collier DA, Ma X, Li T. He ZL, et al. Early Interv Psychiatry. 2012 May;6(2):166-75. doi: 10.1111/j.1751-7893.2011.00291.x. Epub 2011 Sep 23. Early Interv Psychiatry. 2012. PMID: 21951785 - Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B. Ohrmann P, et al. J Psychiatr Res. 2007 Oct;41(8):625-34. doi: 10.1016/j.jpsychires.2006.07.002. Epub 2006 Sep 1. J Psychiatr Res. 2007. PMID: 16949099 - Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis.
Brugger S, Davis JM, Leucht S, Stone JM. Brugger S, et al. Biol Psychiatry. 2011 Mar 1;69(5):495-503. doi: 10.1016/j.biopsych.2010.10.004. Epub 2010 Dec 8. Biol Psychiatry. 2011. PMID: 21145039 Review. - T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.
Bracken BK, Rouse ED, Renshaw PF, Olson DP. Bracken BK, et al. Psychiatry Res. 2013 Aug 30;213(2):142-53. doi: 10.1016/j.pscychresns.2013.03.005. Epub 2013 Jun 12. Psychiatry Res. 2013. PMID: 23769421 Free PMC article. Review.
Cited by
- Meta-analytic evidence of elevated choline, reduced N-acetylaspartate, and normal creatine in schizophrenia and their moderation by measurement quality, echo time, and medication status.
Yang YS, Smucny J, Zhang H, Maddock RJ. Yang YS, et al. Neuroimage Clin. 2023;39:103461. doi: 10.1016/j.nicl.2023.103461. Epub 2023 Jun 27. Neuroimage Clin. 2023. PMID: 37406595 Free PMC article. Review. - Gut and oral microbiome modulate molecular and clinical markers of schizophrenia-related symptoms: A transdiagnostic, multilevel pilot study.
Lee JJ, Piras E, Tamburini S, Bu K, Wallach DS, Remsen B, Cantor A, Kong J, Goetz D, Hoffman KW, Bonner M, Joe P, Mueller BR, Robinson-Papp J, Lotan E, Gonen O, Malaspina D, Clemente JC. Lee JJ, et al. Psychiatry Res. 2023 Aug;326:115279. doi: 10.1016/j.psychres.2023.115279. Epub 2023 May 30. Psychiatry Res. 2023. PMID: 37331068 Free PMC article. - Basal glutamate in the hippocampus and the dorsolateral prefrontal cortex in schizophrenia: Relationships to cognitive proficiency investigated with structural equation modelling.
Stanley JA, Daugherty AM, Richter Gorey C, Thomas P, Khatib D, Chowdury A, Rajan U, Haddad L, Amirsadri A, Diwadkar VA. Stanley JA, et al. World J Biol Psychiatry. 2023 Oct;24(8):730-740. doi: 10.1080/15622975.2023.2197653. Epub 2023 Apr 24. World J Biol Psychiatry. 2023. PMID: 36999359 Free PMC article. - Associations between N-Acetylaspartate and white matter integrity in individuals with schizophrenia and unaffected relatives.
Roberts D, Rösler L, Wijnen JP, Thakkar KN. Roberts D, et al. Psychiatry Res Neuroimaging. 2023 Apr;330:111612. doi: 10.1016/j.pscychresns.2023.111612. Epub 2023 Feb 11. Psychiatry Res Neuroimaging. 2023. PMID: 36805928 Free PMC article. - Functional MRS studies of GABA and glutamate/Glx - A systematic review and meta-analysis.
Pasanta D, He JL, Ford T, Oeltzschner G, Lythgoe DJ, Puts NA. Pasanta D, et al. Neurosci Biobehav Rev. 2023 Jan;144:104940. doi: 10.1016/j.neubiorev.2022.104940. Epub 2022 Nov 2. Neurosci Biobehav Rev. 2023. PMID: 36332780 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical